drugset
drugset / Trial / NCT05052255

RVU120 (SEL120) in Patients with Relapse/Refractory Metastatic or Advanced Solid Tumors

NCT05052255 ↗

Phase 1/2 Active not recruiting 120 enrolled Ryvu Therapeutics SA
NaSingle-groupOpen-labelTreatment

Summary

This is a phase 1/2, dose-escalation and expansion study investigating the safety, pharmacokinetics, and efficacy of RVU120 (SEL120) in patients with metastatic or advanced solid tumors progressing from previous lines of therapy.

Timeline

Start
2021-08-13
Primary completion
2025-05
Completion
2025-05

Drugs

EvaluationDrugModalityDoseRoute
Subject SEL-120 FREE BASE Small molecule — Oral

Indications

neoplasm